As of January 22, 2025, TScan Therapeutics (TCRX) has a market cap of $0.14 billion USD. According to our data, TScan Therapeutics is ranked No.7416 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.14 B |
-10.32%
|
Dec 31, 2024 | $0.16 B |
-47.86%
|
Dec 29, 2023 | $0.30 B |
276.13%
|
Dec 30, 2022 | $80.95 M |
-65.56%
|
Dec 31, 2021 | $0.24 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Legend Biotech
LEGN
|
$6.87 B |
0.000 M
|
USA
|
Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
Precision BioSciences
DTIL
|
$38.13 M |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Market Cap | = | TCRX Stock Price | * | TCRX Shares Outstanding |
= | $2.52 | * | 52.23 M | |
= | $0.14 B |